Determining Whether Intra-Arterial Carboplatin Causes Hearing Loss in Children

Memorial Sloan Kettering Cancer Center (MSK)

Status: Completed

Conditions: Intraocular Retinoblastoma; Hearing Loss

Treatments: Diagnostic Test: Distortion product otoacoustic emission measurement (DPOAE)

Study type: Observational

Funder types: Other

Identifiers

NCT03866460

18-529

Details and patient eligibility

About

The purpose of this study is to find out how often hearing loss occurs in patients with retinoblastoma after receiving treatment with intra-arterial carboplatin.

Enrollment: 30 patients

Sex: All

Ages: 3 months to 18 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Signed informed consent indicating awareness of the investigational nature of the protocol.

• Children with RB aged 3 months and older who are scheduled to receive their first dose of IA carboplatin chemotherapy.

  • Retinoblastoma is rarely seen in children over 8 years old, however we will not include an upper age range so as not to exclude any possible participants

Exclusion criteria

• Children with known and documented preexisting hearing loss.

Trial design

30 participants in 1 patient group

Hearing evaluation DPOAE

Description:

Post IA hearing evaluation will be allowed up until 9 months after IA completion (or roughly one year from initiation of treatment). After completion of standard treatment for RB that included IA carboplatin.

Treatment:

Diagnostic Test: Distortion product otoacoustic emission measurement (DPOAE)